Logo, company name

Welcome to PREDICTOM

International across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.

PREDICTOM Secures €21 Million Investment to Pioneer Early Alzheimer's Detection

PREDICTOM is developing an AI-screening-platform that can identify individuals at risk of developing dementia, even before symptoms manifest. A consortium of 30 partners from academia, business, civil society, and hospitals is steering PRECITOM. 

Read more
A group of people posing for a photo
Graphical user interface

This project has received funding from the Innovative Health Initiative Joint Undertaking, under Grant Agreement nº 101132356. This Joint Undertaking receives support from the European Union’s Horizon Europe research and innovation programme, COCIR, EFPIA, EuropeaBio, MedTechEurope, Vaccines Europe, Novo Nordisk A/S, GN Hearing A/S, Pharmacoidea Hungary, GE HealthCare, Siemens Healthineers, Icometrix Nv Belgium, ALZpath Inc USA, Altoida Inc USA, BrainCheck Inc USA, and Muhdo Health Ltd.

Last updated 11/6/2023